Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21Andrea Bezjak, Frances A. Shepherd, Aleksandra Trajković et al.|Journal of Clinical Oncology|2006Cited by 295
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)Christopher M. Booth, Elizabeth A. Eisenhauer, A. Hilary Calvert et al.|European Journal of Cancer|2007Cited by 109
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Frances A. Shepherd, Keyue Ding et al.|Journal of Thoracic Oncology|2015Cited by 55
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Anthony M. Joshua, Lesley Seymour et al.|Journal of Clinical Oncology|2025Cited by 11